Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers
Status:
Completed
Trial end date:
2020-09-29
Target enrollment:
Participant gender:
Summary
This Phase 1/1b, open-label, first-in-human, monotherapy study will be conducted in 2 parts.
Part A will consist of the SRF231 monotherapy dose-escalation portion of the study, and will
enroll up to 48 patients with advanced solid tumors and hematological cancers. Part B will
include monotherapy expansion cohorts in advanced solid and hematologic cancers to further
examine SRF231 as monotherapy (100 patients total).